{
  "name" : "dacemirror.sci-hub.se_journal-article_fe360fde728154f21d2a9acb8283f506_zhou2016.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Copper-Based Nanomaterials for Cancer Imaging and Therapy",
    "authors" : [ "Min Zhou", "Mei Tian", "Chun Li" ],
    "emails" : [ "meitian@zju.edu.cn", "cli@mdanderson.org" ],
    "sections" : [ {
      "heading" : null,
      "text" : "Subscriber access provided by RMIT University Library\nBioconjugate Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.\nReview\nCopper-Based Nanomaterials for Cancer Imaging and Therapy Min Zhou, Mei Tian, and Chun Li\nBioconjugate Chem., Just Accepted Manuscript • DOI: 10.1021/acs.bioconjchem.6b00156 • Publication Date (Web): 19 Apr 2016\nDownloaded from http://pubs.acs.org on April 20, 2016\nJust Accepted\n“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.\n1\nCopper-Based Nanomaterials for Cancer Imaging and Therapy\nMin Zhou1, 2, 3, Mei Tian2*, Chun Li1*\n1Departments of Cancer Systems Imaging\nThe University of Texas M. D. Anderson Cancer Center\n1881 East Road, Houston, TX 77054\n2Current Address: Department of Nuclear Medicine, The Second Affiliated Hospital of\nZhejiang University School of Medicine, 88 Jiefang Road, Zhejiang University,\nHangzhou, Zhejiang 310009, China\n3Institute of Translational Medicine, Zhejiang University, Hangzhou, Zhejiang 310009,\nChina\n*Corresponding Authors:\nmeitian@zju.edu.cn\ncli@mdanderson.org\nPage 1 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n2\nABSTRACT:\nCopper based nanoparticles (NPs) have attracted increased attention for\nbiomedical applications. Copper chalcogenide NPs exhibit strong absorption in\nnear-infrared region, demonstrate highly efficient light-to-heat transformation under\nnear-infrared laser irradiation, and cause selective thermal destruction to the tumor.\nSmaller copper NPs display its fluorescence signal and capability for optical imaging.\nCopper based NPs also serve as a versatile vehicle for drug delivery and\nimage-guided therapy. This review covers recent advances related to the biomedical\napplication of copper based NPs, with a focus on cancer imaging and therapy. We\nalso discuss challenges to their successful clinical translation.\nPage 2 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n3"
    }, {
      "heading" : "1. INTRODUCTION",
      "text" : "The two major classes of nanoparticles (NPs) with tunable optical absorption in the near-infrared (NIR) region are noble metals and semiconductor NPs.1 The\nabsorption properties of these NPs originate from localized surface plasmon\nresonances (LSPRs). Plasmonic gold NPs of various shapes, such as gold nanoshells,2,3 gold nanorods,4,5 gold nanocages,6 and hollow gold nanospheres,7,8\nhave been explored extensively for biomedical applications, especially for\nphotothermal therapy, (PTT), photoacoustic imaging (PAI), and light-triggered drug delivery.9 However, several important variables, such as complicated and high cost of\nsynthesis, non-degradability, and strong dependence on the dielectric function of the\nsurrounding medium, present considerable obstacles for further development. As an\nalternative to gold NPs, copper based chalcogenide semiconductor NPs, especially\ncopper monosulfide (CuS) NPs, have emerged as a new class of photothermal conducting agent.10-15 CuS NPs can be synthesized using a remarkably simple\nprocess that involves initiating chemical reactions in an aqueous solution. When\ncompared to gold nanostructures, CuS NPs afford several major advantages in terms\nof their translational potential. First, their absorption can be tuned by adjusting the\nparticle size, but only minimally affected by post synthesis treatments or the surrounding environment.16 Second, near-infrared (NIR)-absorbing CuS NPs can be\nformulated to a much smaller size (<20 nm) than could be achieved with any other\ngold nanostructures, which may lead to more favorable pharmacokinetic and\nclearance properties and higher tumor tissue accumulation after systemic\nadministration. Importantly, ultra-small CuS NPs (<6 nm) with strong NIR absorption can be efficiently cleared from the body through the renal system. Third, 64Cu\nradionuclide, a positron emitter with a half-life of 12.7 h, can be integrated into CuS\nNPs during the synthesis without introducing radiometal chelators, and make the radioactive [64Cu]CuS NPs suitable for positron emission tomography (PET) imaging\nPage 3 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n4\nand quantitative tissue analysis. Quantitative image-based analysis can be of a\nsignificant benefit to planning and monitoring of NP-based therapy. Finally, the cost of\nproduction of CuS NPs is much less expensive than for gold nanostructures. Over the\nlast several years, we have investigated the use of CuS NPs in a variety of biomedical applications including molecular imaging and therapy in cancer.10,11,15,17-20 Aside from\nCuS NPs, other copper chalcogenide nanomaterials, such as copper selenide nanocrystals,13 copper telluride nanomaterials etc.,14 and copper oxide NPs etc.,21\nalso have been investigated for their use in cancer imaging and PTT. Moreover, the\nfluorescence properties of copper nanoclusters have been used to image cancer cells.22 23\nIn this review, we will discuss recent progress of plasmonic copper based NPs in\nbiomedical applications, especially in multiple modality cancer imaging [PET,\nphotoacoustic imaging (PAI)] and therapy [PTT, radiotherapy (RT), photodynamic\ntherapy (PDT), and drug delivery]. We will also briefly discuss the future challenges to\nthe successful clinical translation of this class of nanoparticles."
    }, {
      "heading" : "2. COPPER SULFIDE NANOPARTICLES",
      "text" : ""
    }, {
      "heading" : "2.1. Cancer Imaging",
      "text" : "As a discipline at the intersection of molecular biology and the imaging sciences,\nmolecular imaging can allow noninvasive assessment of disease and drug activity at the molecular and cellular levels.24,25 Molecular imaging based on NPs enables\nrepetitive assessment of their biodistribution properties and their clearance mechanisms from the body.26,27 This can aid in addressing critical questions, such as\nspecificity of nanoparticle uptake, the rate of uptake, the distribution of material within\nthe heterogeneous tumor environment, and the rate and routes of clearance from the\ntarget site. Because of their strong NIR absorption and capability for simple\nPage 4 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n5\nincorporation of 64Cu into CuS NPs, they are under investigation as promising contrast agents for PET and PAI.10,17"
    }, {
      "heading" : "2.1.1. PET",
      "text" : "PET is a powerful radionuclide imaging modality that can provide a highly\nsensitive and quantitative readout of an administered radiotracer as a way to assess organ/tissue targeting efficiency and pharmacokinetics.28-30 Because 64Cu and its nonradioactive natural state natCu share the same chemical properties, we exploited\nthis and introduced the concept of chelator-free radioactive NPs by directly incorporating 64Cu into the matrix of CuS NPs.10 When compared to the conventional\nradiolabeling techniques that utilize various radiometal chelators, the most notable\nadvantage of the chelator-free method is its simplicity: there is no need to perform\nextra synthetic steps to conjugate radiometal chelators to NPs. These chelators,\ntogether with radionuclides, may be detached from the surface of NPs after systemic\nadministration, thus confounding interpretation of imaging data. Moreover,\nintroduction of radiometal chelators may significantly alter the surface properties of\nNPs (e.g. charge, hydrophilicity etc.), and thereby influence their pharmacokinetic and\nbiodistribution patterns. Lastly, some radioisotopes may not have appropriate\nchelators available for stable radiolabeling. Since the publication of the work on [64Cu]CuS NPs, several chelator-free radiolabeled NP systems have been reported.31,32 In one such system, positron-emitting arsenic radioisotopes (70/71/72/74As\nor *As) were successfully incorporated into superparamagnetic iron oxide\nnanoparticle (SPION) to yield *As-SPIONs by simply mixing *As (* = 71, 72, 74, or 76) and iron oxide NPs.31 The same strategy has also been applied to 69Ge, a\npositron-emitting radionuclide that is unsuitable for radiolabeling via standard coordination chemistry. 69Ge-labeled SPION were used for dual PET/MRI imaging in vivo.32 Along this line of research, 64Cu was incorporated into CuInS/ZnS quantum dots via chelator-free method for PET and optical imaging,33 and onto the surface of\nPage 5 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n6\nPEG-stabilized Au NPs for PET imaging and PTT.34 A generalized method for\nproducing NPs capable of binding a wide variety of radioisotopes of various oxidation\nstates without selecting corresponding chelators was recently demonstrated with silica-based NPs.35\nPolyethylene glycol (PEG)-coated [64Cu]CuS NPs can be readily synthesized by adding a trace amount of 64CuCl2 into an aqueous solution of natCuCl2 and Na2S in the presence of PEG. The specificity of the resulting [64Cu]CuS NPs can be controlled by adjusting the ratio of 64Cu/natCu in the reaction mixture.10 PEGylated [64Cu]CuS NPs\nexhibited significant uptake and retention in U87 human glioblastoma xenografts in\nmice after intravenous (i.v.) injection as a result of their small size (~ 11 nm in average\ndiameter) and their prolonged blood circulation time. Figure 1 shows representative\nwhole-body micro-PET/CT images of a mouse acquired at 1, 6, and 24 h after i.v. injection of PEG-[64Cu]-CuS NPs. PEG-[64Cu]-CuS NPs gradually accumulated in the\ntumor over the study period, thereby permitting clear visualization of the tumor 24\nhours after injection. Quantitative analysis showed that the average tumor-to-muscle\nratios at 1, 6, and 24 h after NP injection were 2.7:1, 6.1:1, and 6.6:1, respectively, indicating that PEG-[64Cu]-CuS NPs were deposited and retained in the tumor\npossibly as a result of the enhanced permeability and retention (EPR) effect of long-circulating NPs. PEG-[64Cu]CuS NPs were also shown to accumulate and be retained in other tumor models, such as breast cancer xenografts after i.v. injection,18 and thyroid and breast tumors after intratumoral injection.19,20 In these studies,\nquantitative PET imaging data were used to determine dosimetry and plan for PTT of\nthese tumors.\nPage 6 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n7\nAfter systemic administration, most Cu-based NPs eventually accumulated in the\norgans of the mononuclear phagocyte system (MPS), such as the liver and spleen.\nBecause these NPs can be retained in the body for a long period of time, there is\nconcern about their potential long-term risk. To date, it has proven extremely\nchallenging to develop a NP platform that can mediate multi-modal imaging and\ntherapy and, at the same time, can be cleared efficiently from the body with low\nuptake in the liver and spleen. One approach is to develop ultra-small CuS NPs with a size below the renal clearance threshold.36 Toward this end, we have developed\npolyvinylpyrrolidone-coated CuS nanodots (CuS NDs) with an average diameter less than 6 nm.15 To investigate how the size of CuS NPs influenced their in vivo behavior, we compared the pharmacokinetics of 5.6-nm [64Cu]CuS NDs and 19-nm [64Cu]CuS NPs in female Swiss mice. The 5.6-nm [64Cu]CuS NDs displayed significantly lower\narea-under-the curve values, faster systemic clearance, and a shorter terminal half-life than the 19-nm NPs [64Cu]CuS, indicating a less prominent systemic exposure from the smaller NDs.15 Further study showed that the 5.6-nm [64Cu]CuS\nNDs had significantly lower uptake in most major organs at 24 h after i.v. injection. Notably, the liver uptake of the 5.6-nm [64Cu]CuS NDs was only 15% of the uptake of the 19-nm [64Cu]CuS NPs; the spleen uptake of the 5.6-nm [64Cu]CuS NDs was only\nPage 7 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n8\n24% of the uptake of the 19-nm [64Cu]CuS NPs. As shown in µPET/CT images of Swiss mice that were administered i.v. injections of either 5.6-nm [64Cu]CuS NDs or 19-nm [64Cu]CuS NPs, the former was cleared from the body through the kidneys\nwhile the latter was largely taken up by the liver and the spleen (Fig. 2). These data indicate that [64Cu]CuS NDs could effectively evade the MPS."
    }, {
      "heading" : "2.1.2. PAI",
      "text" : "PAI is based on the detection of thermoelastic expansion and ultrasonic signals\ninduced by photothermal expansion of light-absorbing tissues or contrast agents\nunder irradiation of short laser pulses. The technique combines the molecular\nspecificity of optical imaging with the depth and spatiotemporal resolution of sonography.37,38 Although PAI facilitates imaging of biological tissue based on\nendogenous chromophores (oxyhemoglobin and deoxyhemoglobin), its potential\napplications can be significantly expanded by exogenous contrast agents. Exogenous\ncontrast agents with NIR (>700 nm) absorption can be utilized to enhance the\nphotoacoustic signal, due to a relatively low absorption coefficient and a low\nscattering coefficient within this wavelength region, thus providing a relatively clear\nwindow for imaging with optical techniques. Gold nanostructures are the most widely used contrast agents for improvement of PAI.39-42 However, gold nanostructures also\nhave several limitations as contrast agents for PAI, including dependence of optical\nPage 8 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n9\nproperties on shape, size, and geometry of Au NPs and on environmental factors. In\naddition, these NIR-absorbing Au nanostructures usually have relatively large size\nwhich can result in rapid capture by organs of the RES and slow clearance from the body.43-47\nWe initially demonstrated the use of CuS NPs as a novel class of contrast agent for in vivo PAI.17 Notably, most of the currently studied PAI contrast agents (e.g., gold\nnanostructures, organic dyes, etc.) display their maximum absorption between 560-\nand 840-nm. The absorption of CuS NPs could be tuned to peak at wavelengths\ngreater than 900 nm. This make it suitable to use Q-switched Nd:YAG laser, which\nemits laser light at 1064 nm, as the light source for PAI. The Nd:YAG laser at a setting\nof 1064 nm can provide high pulsed energy with a nanosecond pulsed width, which\nshould translate to a stronger PA signal, higher signal-to-noise ratio, and greater\nfield-of-view. Because of the low absorption and scattering coefficient in normal tissue\nat 1064 nm (the second optical window), the strong light absorbed at this wavelength\nby CuS NPs allows deep tissue PAI. Successful CuS NPs mediated PAI of the lymph\nnodes and brain has been achieved in mouse models. Figure 3 illustrates the depth\ncapability of PAI with CuS NPs. At 2.5 cm, all the agarose gel objects were clearly\nvisualized. At a 5 cm depth, the CuS NPs could be imaged with a high in-plane resolution of ∼800 µm and a sensitivity of ∼0.7 nmole per imaging voxel.17 These\npromising findings suggest that CuS NPs may be used for molecular PAI for clinical\napplications, especially for superficial tumor or lesions, such as imaging breast\nlesions up to 5 cm in depth, or possibly other superficial lesions in the skin, lymph\nnodes, limbs, and head and neck.\nPage 9 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n10\nµg/mL (2 OD), ② 50 µg/mL (1 OD), ③ 25 µg/mL (0.5 OD), ④ 12.5 µg/mL (0.25 OD), ⑤\n6.25 µg/mL (0.125 OD), ⑥ gel without contrast agent, and ⑦ two needle tips at center and\n11 O’clock position are embedded; (c) Two dimensional photoacoustic image at the depth of (c) ~ 2.5 cm and (d) ~ 5 cm, from laser illuminated surface. Reprinted with permission from Ref. 17.\nPEGylated CuS NPs have been shown to be suitable for in vivo imaging of tumor\nvasculature. In an orthotopic mouse 4T1 breast tumor model, tumor blood vessel\nstructures, including smaller vessels, could be clearly visualized after i.v. administration of PEG-CuS NPs.18 A recent study on the particle size-dependent\ncontrast enhancement effect of PEGylated CuS NPs for PAI showed superior contrast with smaller NPs (<5 nm) than larger NPs (~7 nm) in vivo.48 This was attributed to\nmore favorable pharmacokinetics and high tumor uptake of smaller CuS NPs than for\nthe larger CuS NPs. Others have reported ultrasmall Cu2-xS nanodots that demonstrated deep tissue PAI and image-guided PTT.49 Interestingly, these Cu2-xS nanodots displayed prolonged circulation in blood at a size lower than the renal\nPage 10 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n11\nclearance threshold (<5 nm). It is possible that Cu2-xS nanodots may have extensive absorption of plasma proteins that increased their apparent size during circulation.\nRecently, Yang et al.50 reported an enzyme-activatable PAI contrast agent based\non CuS NPs for imaging protease activity. In this design, a black hole quencher 3\n(BHQ3) which absorbs red light was conjugated to NIR-absorbing CuS NPs via a\nmatrix metalloproteinases (MMPs)-cleavable peptide linker. Upon cleavage of the\npeptide linker by MMPs in the tumor microenvironment, the small-molecular-weight\norganic dye, BHQ3, was released from the NPs, resulting in an increased PA signal at\n980 nm (from CuS NPs retained in the tumor) over PA signal at 680 nm (from BHQ3 which was washed away from the tumor) during a course of 24 hours.50"
    }, {
      "heading" : "2.1.3. Multimodal Imaging",
      "text" : "Although highly sensitive, the main limitation for PET as a molecular imaging\nmodality is its poor spatial resolution that accounts for the lack of a clear anatomical\nreference frame. PAI, on the other hand, cannot be used for whole body imaging.\nThese limitations can be overcome by integrating PET or PAI with computed\ntomography (CT) or with magnetic resonance imaging (MRI). In the clinic, the\nintegrated examination using PET/CT has gained widespread acceptance as a tool for\ntumor diagnosis, staging, prognosis, treatment planning, and assessment of\ntreatment response. Similarly, PET/MRI has begun to be used as an alternative hybrid\nmodality for clinical applications. Therefore, the combination of PET(PAI)/CT or\nPET(PAI)/MRI may offer new opportunities by providing potentially more\ncomprehensive and accurate information as a result of the complementary features of\nthese technologies. For these reasons, attempts have been made to develop\nplasmonic CuS-based NPs as contrast agents for CT or MRI. Copper ion (II) is\nregarded as a candidate MRI contrast agent because it possesses unpaired electrons.\nIn aqueous solution, the T1 relaxivity (r1) Cu2−xS NPs was measured to be 0.26 mM-1S-1 at 3T, which was substantially lower than that of Gd-DTPA (~4.5 mM-1S-1).\nPage 11 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n12\nNevertheless, contrast enhancement with Cu2−xS NPs was visualized in vivo either after i.v. injection or intratumoral injection. In addition, due to their NIR optical\nabsorption, these NPs also served as efficient contrast agent for enhancing PAI (Fig. 4).51\nRecently, Ni-containing CuS hybrid NPs were presented for PAI/MRI dual\nimaging. The hybrid nanostructures have demonstrated NIR absorption and\nenhanced T1 relaxivity, which is suitable for PAI and MRI respectively. The relaxivity of the hybrid nanostructures was about 2.3 mM−1S−1, which was nearly 8 times higher\nthan that of the corresponding Ni chelate with a ylated multidentate polymer with imidazole pendant groups （PMAH-PEG-Ni2+） These dual modality Ni-CuS hybrid\nNPs were successfully used for in vivo lymph node PAI and MRI.52\nA dual plasmonic hybrid nanostructure composed of Au NPs coated with Cu9S5 showed enhanced optical absorption on the Cu9S5 surface. These NPs also attenuated X-ray due to the presence of Au NPs.53 However, because CT has\nrelatively low detection sensitivity, it is necessary to inject a large amount of Au-Cu9S5\nPage 12 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n13\ncomposite NPs in order to visualize CT contrast enhancement of this type of\nnanomaterials."
    }, {
      "heading" : "2.2. Photothermal Therapy",
      "text" : "We first demonstrated CuS NPs mediated PTT of Hela cancer cells in vitro and of U87 brain tumor in vivo using continuous-wave laser at 808-nm in 2010.10,11 Because\nPEG-CuS NPs have strong NIR absorption with maximum absorbance at\n930-1064nm, we subsequently showed that by using a pulsed laser with 15-ns pulse width, it was possible to have accurate control on the depth of damage zone.18\nThe applications of CuS NPs with different sizes and structures in PTT have been extensively investigated in recent years.10-12,54-64 Two strategies have been explored to\nmodify and optimize the physicochemical properties of Cu2-xS NPs to improve the photothermal conversion efficiency. One approach is to investigate the effect of NPs’\ncomposition, size, and shape on optical absorption properties and photothermal\nconversion efficiency. Thus, hydrophilic Cu9S5 nanocrystals with an average size of 70 nm x 13 nm were found to have a photothermal conversion efficiency of 25.7% with a 980-nm laser.12 Further study led to Cu7.2S4 nanocrystals, which had a photothermal conversion efficiency of 56.7% with a 980-nm laser.55 A flower-like hydrophilic CuS superstructure was prepared by a controlled hydrothermal approach.56 These CuS\nsuperstructures were reported to have photothermal conversion efficiencies 50%\ngreater than that of their corresponding building block, CuS hexagonal nanoplates at\n980 nm. Hollow Cu7S4 nanocrystals also showed effective PTT of cancer cells at a laser power density of 0.72 W/cm2.57 Other interesting CuS nanostructures with excellent photothermal conversion efficiency include nanosuperlattices,58 CuS mesostructures,59 nanoplates,58 and nanoclusters.60 It is well known that particles size\nand size distribution can profoundly influence the pharmacokinetics and tissue\ndistribution pattern of NPs. Therefore, efforts have been made to produce monodisperse Cu2-xS NPs. 65,66 It would be interesting to compare the in vivo\nPage 13 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n14\nbiodistribution and tumor uptake of monodisperse Cu2-xS NPs of different sizes in the same solid tumor models in future studies.\nThe second approach is to introduce different surface coating materials to control\nsize, biocompatibility, and optical properties of CuS NPs. In addition to citric acid and PEG,10 CuS NPs were also coated with cysteine,62 phospholipid-PEG,63 and bovine serum albumin64 to improve biocompatibility. We have found that polyvinylpyrrolidone coating resulted in ultrasmall CuS nanodots.15 CuS NPs could also be coated directly with folic acid to target these NPs to tumor cells that express folate receptors.67"
    }, {
      "heading" : "2.3. Multimodal Therapy",
      "text" : "Single treatment modality is unlikely to completely eradicate residual tumor cells\nand prevent recurrence. Therefore, the ability to integrate multiple treatment\nmodalities in a single nanoparticle system is extremely appealing. Recently, we\ninvestigated the combined PTT and RT using a single agent nanoparticle in anaplastic thyroid cancer.19 64Cu has also been suggested for RT because it has an intermediate half-life (T1/2=12.7 h) and decays through β + emission (0.655 meV, 19%), β- mission (0.573 meV, 40%), and electron capture (41%).68,69 These nuclear properties make 64Cu a suitable radioisotope for PET imaging, radiotherapy applications for cancer with β- particles for bulky tumors, Auger electrons for small tumors, and allow for\naccurate dosimetry determinations. In an orthotopic human Hth83 anaplastic thyroid cancer model, tumor growth was delayed by PEG-[64Cu]CuS NP-mediated RT, PTT,\nand combined therapy, with combined therapy being most effective (Fig. 5a). In\naddition, combined therapy significantly prolonged the survival of Hth83\ntumor-bearing mice compared to other treatments without producing acute toxic side effects.19 Because metastases are the cause of 90% of human cancer deaths, it is\nimportant to show that PTT as a local therapy can be effective in inhibiting tumor spread to distant organs. In this regard, the work by Liu and co-workers70 is worth noting. They investigated PEG-coated, 131I doped CuS NPs, CuS/[131I]I-PEG, for dual RT and PTT. The combined RT and PTT mediated by PEG-CuS/[131I]I demonstrated\nPage 14 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n15\nsynergistic therapeutic effects in the treatment of subcutaneous 4T1 breast tumors (Fig. 5b). Interestingly, with the aid of µPET/CT, PEG-CuS/[131I]I NPs were found to\nmigrate to, and retained in, the sentinel lymph nodes after intratumoral injection.\nCombined RT and PTT applied on those lymph nodes inhibited lung metastasis and prolonged animal survival.70 In a separate study, we also showed that combined RT and PTT mediated by PEG-[64Cu]CuS NP resulted in reduced lung metastasis and prolonged mice bearing orthotopic 4T1 breast tumors.20 Taken together, it is\nconceivable that 4T1 metastasis to the lung may have involved lymphatic drainage\nsystem. Local ablation of primary tumors and/or tumor draining sentinel lymph nodes\nare capable of preventing this route of tumor spread.\nPage 15 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n16\npermission from Ref. 19 and 70.\nPhotodynamic therapy (PDT) is a treatment that uses a photosensitizer and\noxygen to produce reactive oxygen species (ROSs) when exposed to a specific\nwavelength of light. Once exposed to the light, the ROSs kills tumor cells via apoptosis or necrosis.71 Most organic photosensitizers exhibit photodynamic activity\nonly to UV-Vis light, the use of which can result in nonspecific tissue damage. Agents\nthat produce ROS with NIR light would be a welcome addition to the existing options.\nCu2-xS NPs have been shown to possess intrinsic photodynamic activity: they could generate elevated ROS levels under NIR laser light irradiation.72 In a murine B16\nmelanoma model, the combination of Cu2-xS NPs and NIR light resulted in significantly better antitumor activity as demonstrated by the 90% inhibition in tumor growth compared to treatment with NIR light or Cu2-xS NPs alone. 72 Since treatment with Cu2-xS NPs and NIR laser also induced significant temperature elevation, the observed antitumor activity is likely a result of combined PTT and photodynamic\ntherapeutic effects."
    }, {
      "heading" : "2.4. Drug and Gene Delivery",
      "text" : "CuS NPs exhibit interesting properties as drug carriers. Several studies have shown that CuS nanomaterials including hollow nanostructures73 and mesoporous silica nanocomplexes74 could be used to control drug delivery."
    }, {
      "heading" : "2.4.1. Hollow CuS Nanostructures",
      "text" : "The advantages of hollow CuS NPs is their drug delivery capability and sustained\ndrug-release properties due to their mesoporous and hollow structure. Hollow CuS\nNPs were used as a vehicle for enhanced transdermal drug delivery through localized thermal effect of the skin using a nanosecond-pulsed laser.73 Hollow CuS NPs were\nalso coated with chitosan for the delivery of an immunostimulatory agent that enhances immunotherapy (Fig. 6a).75 In this study, it was shown that PTT-induced\nrelease of tumor antigens into the surrounding milieu, while CpG potentiated host\nPage 16 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n17\nantitumor immunity. The results demonstrated that combined photothermal\nimmunotherapy is more effective than either immunotherapy or PTT alone against\nprimary (treated) and distant (untreated) tumors. Because hollow CuS NPs possess\nlarge specific surface volumes and numerous mesoporous pores, one could efficiently\nload them with hydrophobic drug molecules. For example, camptothecin was loaded\nonto hollow CuS NPs, and its release from the NPs could be remotely controlled using a 980-nm NIR laser.76 Synergistic antitumor activity was achieved by integrating PTT\nand chemotherapy enabled by a single NP system. In another study, CuS nanocages\nwere synthesized using a solid–liquid reaction between Cu2O nanocubes and thiourea.77 CuS nanocages displayed exceptionally high drug loading capacity for\ndoxorubicin (DOX) and released the anticancer drug in a pH-dependent fashion. Such\nstrategies to develop multifunctional NPs is a promising avenue for enhancing\nantitumor efficacy.\nPage 17 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n18\nchitosan-coated HCuSNPs. “Chi-CpG-NPs” represents chitosan-CpG nanocomplexes. “SCuSNPs” represents small CuS NPs. (b) Schematic illustration of the synthetic protocol of the Cu9S5 @mSiO2-PEG core-shell nanocomposites. And schematic illustration of the nanocomposites as a multifunctional nanoplatform for combining photothermal- and chemotherapy with infrared thermal imagining for cancer treatment. Reprinted with permission from ref 74 and 75."
    }, {
      "heading" : "2.4.2. Mesoporous Silica - CuS Nanostructures",
      "text" : "Mesoporous silica is a form of silica that contains pores that are 2-50 nm in\ndiameter. The large surface area of the pores of mesoporous silica NPs allows the particles to be filled with drugs or imaging agents. Song et al.74 coated CuS\nnanocrystals with a mesoporous silica (mSiO2) shell to form Cu9S5@mSiO2-PEG core–shell nanostructures for cancer drug delivery (Fig. 6b). The mesoporous silica\nshell is provided as the carrier for loading DOX, and the release of DOX from the\nnanostructures could be triggered by pH and NIR light. The same group also\nconjugated folic acid to CuS@mSiO2-PEG core-shell nanostructures for targeted delivery.78 In another study, DOX loaded core-shell Cu9S5@mSiO2 NPs were incorporated into poly(ε-caprolactone) and gelatin to form nanofibrous fabrics using\nan electrospinning process. The resultant composite fibers could be implanted directly\nin the tumor to achieve combined chemotherapy of the controlled release of DOX from mesoporous silica and PTT with the imbedded Cu9S5 NPs. 79 Several other CuS NP - mesoporous silica systems based on similar concepts have been developed and tested.80,81 In one system, mesoporous silica was conjugated to CuS NPs with two complementary DNA sequences.80 In this scenario, CuS NPs acted as both a\ngatekeeper, preventing premature release of drugs, and as a photothermal\nconducting agent for ablation of cancer cells."
    }, {
      "heading" : "2.5. Image-Guided Therapy",
      "text" : "Image-guided therapy of cancer uses a variety of imaging technologies to plan\nPage 18 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n19\nthe best surgical or other therapeutic approach before treatment, or during treatment to visualize the procedure.82,83 Integration of imaging capability into the design of NPs\nmade it possible to achieve an enhancement of signal to background ratio in the targeted volume and to monitor the distribution of NPs in real-time.26,84 This allows\nadjustment of cancer treatments to optimize outcome according to pharmacokinetics\nand tumor uptake of NPs in individual patients. Imaging modalities that have been used for noninvasive imaging of CuS NPs include PET,10,18 MRI,85,86 PAI,87-89 and CT.90\nPEG-[64Cu]CuS NPs have been utilized for PET imaging and image-guided PTT in various tumor models.10,18,19 For example, PET-guided PTT mediated by PEG-[64Cu]CuS NPs were used to quantify uptake of the NPs in thyroid and breast tumor models.18,19 MicroPET imaging of 4T1 breast tumor-bearing mice showed a\ngradual accumulation of NPs in the tumor over time. About 6.5% of the injected dose was taken up in each gram of tumor tissue at 24 h after i.v. injection of PEG-[64Cu]CuS NPs. These data were used to select laser power and treatment duration. 64Cu was\nalso used to label a CuS NP-based drug delivery system composed of CuS NPs\nencapsulated in mesoporous silica (MSN) shells, which was then loaded with DOX and decorated with TRC105 antibody for vasculature targeting.91 In this study, PET\nwas used to guide PTT-chemotherapy mediated by these CuS@MSN NPs.\nPAI also guided CuS NPs based PTT, chemotherapy, and their combination.18 87,88 NIR absorption of PEG-CuS NPs allowed for simultaneous PAI and PTT.18 PAI\nrevealed that the blood vasculature of tumors was enhanced significantly after\nintravenous injection of PEG-CuS NPs. Successful PTT was implemented with dual\nPET/PAI guidance. Several other groups have taken advantage of the strong NIR\nabsorption of Cu2-xS NPs and reported various nanostructures incorporating Cu2-xS NPs for PAI-guided PTT or PTT-chemotherapy.87-89\nMRI offers high resolution images, particularly for soft tissues. To make CuS NP-based nanostructures MRI-visible, Tian et al.85 synthesized Fe3O4@Cu2–xS core-shell NPs. Because of their strong absorption in the NIR region, these NPs\nPage 19 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n20\nexhibited high photothermal stability and superparamagnetic properties, making them suitable for T2-weighted MRI and infrared thermal imaging (Fig. 7). Xiao et al.92\nsynthesized a novel multifunctional core/satellite nanostructure composed of\nsilica-coated rare-earth upconversion nanoparticles (NaYbF4:2%Er 3+/20%Gd3+@SiO2−NH2) as the core and ultrasmall CuS NPs as the satellites for synergistic RT/PTA therapy. These nanostructures possessed excellent\nMR and CT contrast, and displayed photon up-conversion luminescence in which\nlow-energy NIR photons are converted to higher-energy ones (shorter wavelengths). The authors noted that in addition to Gd3+ ions, Cu2+ with one unpaired electron in the\ncore-satellite nanostructures, may have also contributed to the strong T1 MR signal\nenhancement observed in this system. Thus, not only can these multi-functional NPs\nconvert NIR light into heat for effective thermal ablation but also induce a highly\nlocalized radiation dose boost to trigger enhanced radiation damage. These\nprocedures can be potentially done under MRI/CT/optical trimodal imaging guidance.\nPage 20 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n21\nCross-sectional snap shots of T2-weighted MRI scan of the nude mouse before and after being\ninjected with the NPs, respectively. (c) Photograph of the tumor-bearing mouse, infrared\nthermal image of the tumor-bearing mouse treated with the nanoparticles after a 980 nm laser\nirradiation for 2 min. (c) In vivo Fe3O4@Cu2−xS NPs induced photothermal therapy of tumor.\nReprinted with permission from Ref 85."
    }, {
      "heading" : "3. COPPER CHALCOGENIDE AND COPPER OXIDE",
      "text" : "NANOPARTICLES\nSeveral other types of copper-containing NIR-absorbing nanomaterials have been\nPage 21 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n22\ndeveloped and tested for PTT. Hessel et al.13 prepared copper selenide (Cu2-xSe)\nnanocrystals with an average diameter of ∼16 nm and an intense NIR absorbance\npeak. Under 800-nm NIR light irradiation, the Cu2–xSe nanocrystals produced significant photothermal heating effects, and resulted in destruction of human\ncolorectal cancer cells in vitro. Cu2–xSe nanocrystals with a diameter of ∼ 7.6 nm were used as a contrast agent for in vivo PAI of sentinel lymph node in a rat model.93 The\nestimated PA sensitivity of Cu2–xSe nanocrystals was 1.7 nM, which is comparable to that of NIR-absorbing gold nanostructures. Recently, the synthesis of highly monodispersed CuTe nanocubes, nanoplates, and nanorods were reported.14 The\nsynthesis was based on the reaction of a copper salt with trioctylphosphine telluride in\nthe presence of lithium bis(trimethylsilyl) amide and oleylamine. In particular, CuTe\nnanocubes were found to displayed a strong NIR absorption associated with localized\nsurface plasmon resonance. CuTe nanocubes could be used as surface-enhanced Raman spectroscopy (SERS) probes as well as photothermal agents. Li et al.90 report\na one-pot solvothermal route to synthesize copper bismuth sulfide (Cu3BiS3) nanostructures. These NPs exhibited multiple intrinsic properties useful for PTT (due\nto NIR absorption), CT contrast enhancement (due to the large X-ray attenuation\ncoefficient of bismuth) and NIR fluorescence imaging (due to photoluminescence\nemission in the NIR range). Recently, copper oxide NPs were proposed as a contrast agent for dual MRI and ultrasound imaging. 21"
    }, {
      "heading" : "4. COPPER NANOCLUSTERS",
      "text" : "Recently, copper nanoclusters were evaluated for applications in fluorescence imaging and therapy of cancer.22,23,94 Ultra-small copper nanoclusters which are\ncomposed of a few to a hundred Cu atoms, demonstrate molecule-like properties\nincluding discrete electronic states and size-dependent fluorescence, making them\nsuitable fluorescence imaging agents for biomedical applications. For example, Zhao\nPage 22 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n23\net al.94 reported a one-pot approach to synthesize transferrin (Trf)-functionalized\ncopper nanoclusters (Trf-Cu NCs) via a bio-mineralization process with Trf as the\ntemplate and ascorbic acid as a reducing agent. Trf-Cu NCs showed an intense red\nfluorescence with a red emission peak at 670 nm (quantum yield about 6.2%). This\nred-emitting fluorescent probe was evaluated for molecular imaging of cancer cells.\nSeveral other studies on the use of copper NPs as fluorescent probes were also reported.95-98\nCopper nanoclusters could also be used for MRI and PET imaging with appropriate modification. Thus, Wang et al.99 prepared copper nanoclusters for dual\nMRI and fluorescence imaging because of the red fluorescence and paramagnetic properties of the nanoclusters. Yang et al.100 directly labeled copper NPs (CuNPs) with 64Cu using a chelator-free method. They compared renal clearance of\ndegradable glutathione coated (GS-CuNPs) and their dissociated products,\ncomprised of Cu(II)-glutathione disulfide complexes (Cu(II)-GSSG), and found that\nthe renal clearance of GS-CuNPs was much faster than for Cu(II)-GSSG. This was\nattributed to less serum protein absorption to GS-CuNPs than to Cu(II)-GSSG. This\nand another study on ultra-small renal clearable Cu-based NPs illustrate the importance of size and serum protein absorption to efficient body clearance of NPs.15\nCuNPs could induce DNA degradation in a dose dependent manner.101 The fact\nthat singlet oxygen scavengers such as sodium azide and tris[hydroxyl methyl] amino\nmethane could prevent the DNA degrading action of CuNPs implicated the\ninvolvement of ROS in the degradation process. By combining cisplatin and CuNPs in\na hydrogel nanoparticle, it was shown that the ROS generated from CuNPs further\nenhanced the efficacy of cisplatin in killing tumor cells, thus demonstrating a synergistic mode of action.102\n5. TOXICITY OF COPPER BASED NANOPARTICLES\nPage 23 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n24\nTranslation of NPs into clinical practice has been limited due to toxicities induced\nby nonspecific accumulation of NPs in healthy organs after systemic administration.103-105 Although many reports have demonstrated the utility of copper\nbased NPs as contrast and/or therapeutic agents for cancer imaging and therapy, the\npotential toxic effects of copper based NPs remain poorly defined.\nCopper is required for the function of over 30 proteins, including superoxide\ndismutase and cytochrome c oxidase. It is an essential trace element in the body.\nHomeostasis of Cu ions in the body is the result of a balance between absorption and excretion by the biliary system.106 However, excess free Cu ions could cause impaired cellular functions and even cell death.107 For CuS NPs, the solubility is very low (~6 × 10−37 at 25°C), which indicates that CuS is very stable, and should not lead to\nsignificant toxicity. Indeed, CuS NPs appeared to have low in vitro cytotoxicity, comparable to that of gold NPs.11\nFeng et al.108 recently reported the organ and cellular toxicities of CuS nanoplates.\nCuS nanoplates had an average edge length of 59.4 nm, a mean thickness of 23.8\nnm, and average hydrodynamic size of 102 nm in aqueous dispersion. In vitro CuS\nnanoplates caused a time-, concentration- and cell type-dependent suppression of\ngrowth in all 4 cell lines tested. In vivo, the maximum tolerated dose and lethal dose\n50 (LD50) in immune-competent mice were determined to be 8.66 and 54.5 mg/kg, respectively, over a 7-day observation period. Results from a sub-chronic toxicity test\n(1 month) indicated that there were no obvious effects on blood chemistry, body\nweight, and histology of major organs at test doses of 0.55 - 5.50 mg/kg (<1/10 of\nLD50). However, many residual CuS nanoplates were found localized in the spleen, liver, kidney and lung 48 h after injection. A small fraction of CuS nanoplates were\neliminated through the liver and gallbladder to the intestine (~11% of injected dose)\nand through the kidney to the bladder (~4% injected dose). The potential long-term\neffects of CuS nanoplates and other CuS NPs remain to be defined.\nPage 24 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n25\nTo address the issue of prolonged tissue retention, a recent study compared the\ndegradability and toxicity between hollow CuS NPs and PEGylated hollow gold nanospheres in mice after intravenous administration.109 The histological and\nbiochemical results showed that both NPs did not induce significant toxicity during the\n3-month study. Hollow CuS NPs (~70 nm in average diameter) were found to be\nexcreted from the body through both hepatobiliary (67% percentage of injected dose)\nand renal (23% of injected dose) routes over a 1-month period. Body clearance of\nhollow CuS NPs was most probably attributable to degradation of the NPs into smaller\nparticles and gradual dissociation of CuS into soluble ions. This may explain the\nobserved reversible change in the proteomic profile in mice receiving hollow CuS\nNPs.\nCuS NPs that could be readily cleared from the body may overcome one of the\nmajor barriers in clinical translation of functional NPs, that is, toxic effects due to nonspecific accumulation of NPs in healthy organs.36,110 We recently demonstrated a\nnew multifunctional, ultrasmall (< 6 nm) photothermal conversion agent,\npoly-vinylpyrrolidone coated CuS nanodots (CuS NDs), which has minimal\nnonspecific uptake in the RES organs and can be efficiently cleared from the body via the renal urinary system.15 According to PET imaging and biodistribution data, we\nfound that more than 95% of CuS NDs is cleared from the body 24 h after intravenous\ninjection. MicroPET/CT images of Swiss mice acquired at different times after i.v. injection of 5.6 nm [64Cu]CuS NDs are presented in Figure 2a. At 10 min after\ninjection, the dominant PET signal was in the bladder and the kidney. By 2 h after\ninjection, the PET signal in the kidney was significantly decreased, indicating that the renal clearance of [64Cu]CuS NDs occurred primarily during the first 2 h after NP\ninjection. By 24 h after ND injection, PET signals were no longer discernible in the mice. These data indicate that the majority of [64Cu]CuS NDs were eliminated from the\nbody by 24 h after injection. In contrast, at 10 min, 2 h, and 24 h after i.v. injection of\nthe 19 nm CuS NPs, the majority of radioactivity remained in the liver (Figure 2b).\nPage 25 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n26\nThus, particle size appears to be the primary factor accounting for evasion of the MPS\nby CuS NDs. An initial dose finding toxicity study of CuS NDs showed that all mice\nsurvived after an injected dose of up to 60 mg/kg. This dose was 15 times greater\nthan the effective dose used in the in vivo PTA of 4T1 tumors. Preliminary acute blood\nbiochemistry and hematology studies showed that treatment with CuS NDs at doses\nup to 80 mg/kg did not affect liver function, kidney functions, and blood chemistry.\nTherefore, CuS NDs appear to have a relatively safe toxicity profile in mice. These\ndata suggest that such ultra-small NPs have great opportunity for clinical applications."
    }, {
      "heading" : "6. CONCLUSION AND FUTURE PERSPECTIVES",
      "text" : "In this review, we have discussed in detail the application of copper based NPs,\nespecially for CuS NPs, for in vivo cancer imaging, PTT, drug delivery, image-guided\ntherapy, and reported on early strategies to mitigate potential toxicities. Compared to\nother inorganic nanomaterials, such as gold nanoshells, gold nanorods, and carbon\nnanotubes, CuS NPs have not been studied extensively. However, the number of\nliterature reports dealing with CuS NPs in biomedical applications is growing.\nBecause of their multifunctional characteristics, CuS NPs are ideal materials for\ntheranostic applications: they can serve as nuclear tracers or contrast agents for a\nvariety of imaging and diagnostic techniques; they can destroy cancer cells through\nphotothermal effects; they can release drugs in a controlled manner in response to an\nexternal stimulus. Significantly, all these features can be readily integrated in a single\nsystem to fulfill both diagnostic and therapeutic requirements.\nDespite many positive results in vitro and in vivo, much more effort should be\nfocused on the in vivo properties and disposition of copper based NPs, including their\npharmacodynamics, pharmacokinetics, and potential long-term toxicity before appropriated imaging and therapeutic strategies are tested in cancer patients.101, 102\nWith regard to the toxicology of CuS NPs, the data available to date are limited and\nPage 26 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n27\nfragmentary; more in vivo experiments are needed for a comprehensive\nunderstanding and assessment of CuS toxicity. Moreover, it would be interesting and\nimportant to compare the different CuS NP agents side-by-side, to evlauate the\nadvantages and limitations of each agent, as well as identify the most promising ones\nwith high photothermal conversion efficiency, optimal in vivo pharmacology, and\nmanageable long-term toxicity.\nWe hope this review has given the reader a sense of the great potential of copper\nbased NPs for a diverse array of applications in both cancer imaging and therapy. As\nwe and other groups continue to explore this interesting and promising nano-material,\nthe unique features of Cu NPs and numerous ways in which the properties can be\nmodified will likely lead to the development of more novel and exciting stand-alone\ntechniques and highly effective combinations of existing ones."
    }, {
      "heading" : "ACKNOWLEDGEMENTS",
      "text" : "We thank Louis R. De Palatis for editing the manuscript. This work was supported by\nthe John S. Dunn Foundation.\nAUTHOR INFORMATION\nCorresponding Author\n*E-mail:\nmeitian@zju.edu.cn\ncli@mdanderson.org\nNOTES\nThe authors declare no competing financial interest.\nPage 27 of 40\nACS Paragon Plus Environment\nBioconjugate Chemistry\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n28"
    } ],
    "references" : [ {
      "title" : "Functional nanomaterials for phototherapies of cancer",
      "author" : [ "L. Cheng", "C. Wang", "L. Feng", "K. Yang", "Z. Liu" ],
      "venue" : "Chem. Rev",
      "citeRegEx" : "Cheng et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Cheng et al\\.",
      "year" : 2014
    }, {
      "title" : "Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance",
      "author" : [ "L.R. Hirsch", "R.J. Stafford", "J.A. Bankson", "S.R. Sershen", "B. Rivera", "R.E. Price", "J.D. Hazle", "N.J. Halas", "J.L. West" ],
      "venue" : "P. Natl. Acad. Sci. USA",
      "citeRegEx" : "Hirsch et al\\.,? \\Q2003\\E",
      "shortCiteRegEx" : "Hirsch et al\\.",
      "year" : 2003
    }, {
      "title" : "Bifunctional gold nanoshells with a superparamagnetic iron oxide-silica core suitable for both MR imaging and photothermal therapy",
      "author" : [ "X. Ji", "R. Shao", "A.M. Elliott", "R.J. Stafford", "E. Esparza-Coss", "J.A. Bankson", "G. Liang", "Z. Luo", "K. Park", "Markert", "J. T" ],
      "venue" : "J. Phys. Chem. C",
      "citeRegEx" : "Ji et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Ji et al\\.",
      "year" : 2007
    }, {
      "title" : "Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods",
      "author" : [ "X.H. Huang", "I.H. El-Sayed", "W. Qian", "M.A. El-Sayed" ],
      "venue" : "J. Am. Chem",
      "citeRegEx" : "Huang et al\\.,? \\Q2006\\E",
      "shortCiteRegEx" : "Huang et al\\.",
      "year" : 2006
    }, {
      "title" : "Plasmonic photothermal therapy (PPTT) using gold nanoparticles",
      "author" : [ "X. Huang", "P.K. Jain", "I.H. El-Sayed", "M.A. El-Sayed" ],
      "venue" : "Lasers Med",
      "citeRegEx" : "Huang et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Huang et al\\.",
      "year" : 2008
    }, {
      "title" : "Immuno gold nanocages with tailored optical properties for targeted photothermal destruction of cancer cells",
      "author" : [ "J. Chen", "D. Wang", "J. Xi", "L. Au", "A. Siekkinen", "A. Warsen", "Z.Y. Li", "H. Zhang", "Y. Xia", "X. Li" ],
      "venue" : "Nano Lett",
      "citeRegEx" : "Chen et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Chen et al\\.",
      "year" : 2007
    }, {
      "title" : "In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy",
      "author" : [ "M.P. Melancon", "W. Lu", "Z. Yang", "R. Zhang", "Z. Cheng", "A.M. Elliot", "J. Stafford", "T. Olson", "J.Z. Zhang", "C. Li" ],
      "venue" : "Mol. Cancer Ther",
      "citeRegEx" : "Melancon et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Melancon et al\\.",
      "year" : 2008
    }, {
      "title" : "Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres",
      "author" : [ "W. Lu", "C.Y. Xiong", "G.D. Zhang", "Q. Huang", "R. Zhang", "J.Z. Zhang", "C. Li" ],
      "venue" : "Clin. Cancer Res",
      "citeRegEx" : "Lu et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Lu et al\\.",
      "year" : 2009
    }, {
      "title" : "Cancer theranostics with near-infrared light-activatable multimodal nanoparticles",
      "author" : [ "M.P. Melancon", "M. Zhou", "C. Li" ],
      "venue" : "Acc. Chem. Res",
      "citeRegEx" : "Melancon et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Melancon et al\\.",
      "year" : 2011
    }, {
      "title" : "A chelator-free multifunctional [64Cu]CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy",
      "author" : [ "M. Zhou", "R. Zhang", "M.A. Huang", "W. Lu", "S.L. Song", "M.P. Melancon", "M. Tian", "D. Liang", "C. Li" ],
      "venue" : "J. Am. Chem",
      "citeRegEx" : "Zhou et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Zhou et al\\.",
      "year" : 2010
    }, {
      "title" : "Copper sulfide nanoparticles for photothermal ablation of tumor cells",
      "author" : [ "Y.B. Li", "W. Lu", "Q.A. Huang", "M.A. Huang", "C. Li", "W. Chen" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "Li et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Li et al\\.",
      "year" : 2010
    }, {
      "title" : "Copper selenide nanocrystals for photothermal therapy",
      "author" : [ "C.M. Hessel", "V.P. Pattani", "M. Rasch", "M.G. Panthani", "B. Koo", "J.W. Tunnell", "B.A. Korgel" ],
      "venue" : "Nano Lett",
      "citeRegEx" : "Hessel et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Hessel et al\\.",
      "year" : 2011
    }, {
      "title" : "CuTe nanocrystals: shape and size control, plasmonic properties, and use as SERS probes and photothermal agents",
      "author" : [ "W.H. Li", "R. Zamani", "P.R. Gil", "B. Pelaz", "M. Ibanez", "D. Cadavid", "A. Shavel", "R.A. Alvarez-Puebla", "W.J. Parak", "J Arbiol" ],
      "venue" : "J. Am. Chem",
      "citeRegEx" : "Li et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Li et al\\.",
      "year" : 2013
    }, {
      "title" : "CuS nanodots with ultrahigh efficient renal clearance for positron emission tomography imaging and image-guided photothermal therapy",
      "author" : [ "M. Zhou", "J. Li", "S. Liang", "A.K. Sood", "D. Liang", "C. Li" ],
      "venue" : "ACS Nano",
      "citeRegEx" : "Zhou et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Zhou et al\\.",
      "year" : 2015
    }, {
      "title" : "Reversible tunability of the near-infrared valence band plasmon resonance in Cu2–xSe nanocrystals",
      "author" : [ "D. Dorfs", "T. Härtling", "K. Miszta", "N.C. Bigall", "M.R. Kim", "A. Genovese", "A. Falqui", "M. Povia", "L. Manna" ],
      "venue" : "J. Am. Chem",
      "citeRegEx" : "Dorfs et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Dorfs et al\\.",
      "year" : 2011
    }, {
      "title" : "Theranostic probe for simultaneous in vivo photoacoustic imaging and confined photothermolysis by pulsed laser at 1064 nm in 4T1 breast cancer",
      "author" : [ "M. Zhou", "G. Ku", "L. Pageon", "C. Li" ],
      "venue" : "model. Nanoscale",
      "citeRegEx" : "Zhou et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Zhou et al\\.",
      "year" : 2014
    }, {
      "title" : "Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer",
      "author" : [ "M. Zhou", "Y. Chen", "M. Adachi", "X. Wen", "B. Erwin", "O. Mawlawi", "S.Y. Lai", "C. Li" ],
      "venue" : "Biomaterials",
      "citeRegEx" : "Zhou et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Zhou et al\\.",
      "year" : 2015
    }, {
      "title" : "Radio-photothermal therapy mediated by a single compartment nanoplatform depletes tumor initiating cells and reduces lung metastasis in orthotopic 4T1 breast tumor model",
      "author" : [ "M. Zhou", "J. Zhao", "S. Song", "R. Zhang", "S. Gupta", "D. Tan", "H. Shen", "F. Mauro", "C. Li" ],
      "venue" : "Nanoscale",
      "citeRegEx" : "Zhou et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Zhou et al\\.",
      "year" : 2015
    }, {
      "title" : "Copper oxide nanoparticles as contrast agents for MRI and ultrasound dual-modality imaging",
      "author" : [ "O. Perlman", "I. Weitz", "H. Azhari" ],
      "venue" : "Phys. Med. Biol",
      "citeRegEx" : "Perlman et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Perlman et al\\.",
      "year" : 2015
    }, {
      "title" : "Green synthesis of peptide-templated fluorescent copper nanoclusters for temperature sensing and cellular imaging",
      "author" : [ "H. Huang", "H. Li", "A.J. Wang", "S.X. Zhong", "K.M. Fang", "J.J. Feng" ],
      "venue" : null,
      "citeRegEx" : "Huang et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Huang et al\\.",
      "year" : 2014
    }, {
      "title" : "Blue-emitting copper nanoclusters synthesized in the presence of lysozyme as candidates for cell labeling",
      "author" : [ "R. Ghosh", "A.K. Sahoo", "S.S. Ghosh", "A. Paul", "A. Chattopadhyay" ],
      "venue" : "ACS App. Mater. Interfaces",
      "citeRegEx" : "Ghosh et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Ghosh et al\\.",
      "year" : 2014
    }, {
      "title" : "Molecular imaging in drug development",
      "author" : [ "J.K. Willmann", "N. van Bruggen", "L.M. Dinkelborg", "S.S. Gambhir" ],
      "venue" : "Nat. Rev. Drug Discov",
      "citeRegEx" : "Willmann et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Willmann et al\\.",
      "year" : 2008
    }, {
      "title" : "Molecular imaging in cancer",
      "author" : [ "R. Weissleder" ],
      "venue" : "Science",
      "citeRegEx" : "Weissleder,? \\Q2006\\E",
      "shortCiteRegEx" : "Weissleder",
      "year" : 2006
    }, {
      "title" : "Multimodality imaging probes: design and challenges",
      "author" : [ "A. Louie" ],
      "venue" : "Chem. Rev",
      "citeRegEx" : "Louie,? \\Q2010\\E",
      "shortCiteRegEx" : "Louie",
      "year" : 2010
    }, {
      "title" : "Molecular imaging with theranostic",
      "author" : [ "J.V. Jokerst", "S.S. Gambhir" ],
      "venue" : null,
      "citeRegEx" : "Jokerst and Gambhir,? \\Q2011\\E",
      "shortCiteRegEx" : "Jokerst and Gambhir",
      "year" : 2011
    }, {
      "title" : "Molecular imaging",
      "author" : [ "S.M. Ametamey", "M. Honer", "P.A. Schubiger" ],
      "venue" : "imaging. J. Nucl. Med",
      "citeRegEx" : "Ametamey et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Ametamey et al\\.",
      "year" : 2008
    }, {
      "title" : "Molecular imaging of cancer",
      "author" : [ "M. Shokeen", "C.J. Anderson" ],
      "venue" : "PET. Chem. Rev. 108,",
      "citeRegEx" : "Shokeen and Anderson,? \\Q2009\\E",
      "shortCiteRegEx" : "Shokeen and Anderson",
      "year" : 2009
    }, {
      "title" : "Intrinsically radioactive",
      "author" : [ "D.O. Kiesewetter", "J. Chang", "X. Chen" ],
      "venue" : null,
      "citeRegEx" : "Kiesewetter et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Kiesewetter et al\\.",
      "year" : 2015
    }, {
      "title" : "Chelator-free (64)Cu-integrated gold",
      "author" : [ "W. Zhu", "G Niu" ],
      "venue" : null,
      "citeRegEx" : "P. et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "P. et al\\.",
      "year" : 2014
    }, {
      "title" : "Silica nanoparticles as substrates for chelator-free",
      "author" : [ "J. Grimm" ],
      "venue" : null,
      "citeRegEx" : "F. and Grimm,? \\Q2015\\E",
      "shortCiteRegEx" : "F. and Grimm",
      "year" : 2015
    }, {
      "title" : "Photoacoustic tomography: in vivo imaging from organelles to organs",
      "author" : [ "L.V. Wang", "S. Hu" ],
      "venue" : "Science",
      "citeRegEx" : "Wang and Hu,? \\Q2012\\E",
      "shortCiteRegEx" : "Wang and Hu",
      "year" : 2012
    }, {
      "title" : "In vivo photoacoustic tomography of chemicals: high-resolution functional and molecular optical imaging at new depths",
      "author" : [ "C. Kim", "C. Favazza", "L.V. Wang" ],
      "venue" : "Chem. Rev",
      "citeRegEx" : "Kim et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Kim et al\\.",
      "year" : 2010
    }, {
      "title" : "Gold nanocages as contrast agents for photoacoustic imaging",
      "author" : [ "W. Li", "P.K. Brown", "L.V. Wang", "Y. Xia" ],
      "venue" : "Contrast Media Mol. Imaging",
      "citeRegEx" : "Li et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Li et al\\.",
      "year" : 2011
    }, {
      "title" : "Photoacoustic imaging of multiple targets using gold nanorods",
      "author" : [ "P.C. Li", "C.W. Wei", "C.K. Liao", "C.D. Chen", "K.C. Pao", "C.R. Wang", "Y.N. Wu", "D.B. Shieh" ],
      "venue" : "IEEE Trans. Ultrason. Ferroelectr. Freq. Control",
      "citeRegEx" : "Li et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Li et al\\.",
      "year" : 2007
    }, {
      "title" : "Gold nanorods as molecular contrast agents in photoacoustic imaging: the promises and the caveats",
      "author" : [ "S. Manohar", "C. Ungureanu", "T.G. Van Leeuwen" ],
      "venue" : "Contrast Media Mol. Imaging",
      "citeRegEx" : "Manohar et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Manohar et al\\.",
      "year" : 2011
    }, {
      "title" : "Photoacoustic imaging of living mouse brain vasculature using hollow gold nanospheres",
      "author" : [ "W. Lu", "Q. Huang", "G. Ku", "X. Wen", "M. Zhou", "D. Guzatov", "P. Brecht", "R. Su", "A. Oraevsky", "L.V. Wang", "C. Li" ],
      "venue" : "Biomaterials",
      "citeRegEx" : "Lu et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Lu et al\\.",
      "year" : 2010
    }, {
      "title" : "Impact of PEGylation on the biological effects and light heat conversion efficiency of gold nanoshells on silica nanorattles",
      "author" : [ "H. Liu", "T. Liu", "H. Wang", "L. Li", "L. Tan", "C. Fu", "G. Nie", "D. Chen", "F. Tang" ],
      "venue" : "Biomaterials",
      "citeRegEx" : "Liu et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 2013
    }, {
      "title" : "Size dependent cellular uptake, in vivo fate and light-heat conversion efficiency of gold nanoshells on silica nanorattles",
      "author" : [ "H. Liu", "T. Liu", "L. Li", "N. Hao", "L. Tan", "X. Meng", "J. Ren", "D. Chen", "F. Tang" ],
      "venue" : "Nanoscale",
      "citeRegEx" : "Liu et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 2012
    }, {
      "title" : "In vivo PET imaging and biodistribution of radiolabeled gold nanoshells in rats with tumor xenografts",
      "author" : [ "H. Xie", "Z.J. Wang", "A. Bao", "B. Goins", "W.T. Phillips" ],
      "venue" : "Inter. J. Pharm",
      "citeRegEx" : "Xie et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Xie et al\\.",
      "year" : 2010
    }, {
      "title" : "Targeted photothermal ablation of murine melanomas",
      "author" : [ "W. Lu", "C. Xiong", "G. Zhang", "Q. Huang", "R. Zhang", "J.Z. Zhang", "C. Li" ],
      "venue" : null,
      "citeRegEx" : "Lu et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Lu et al\\.",
      "year" : 2009
    }, {
      "title" : "Pharmacokinetics, clearance, and biosafety of polyethylene glycol-coated hollow gold nanospheres",
      "author" : [ "J. You", "J. Zhou", "M. Zhou", "Y. Liu", "J.D. Robertson", "D. Liang", "C. Van Pelt", "C. Li" ],
      "venue" : "Part. Fibre Toxicol",
      "citeRegEx" : "You et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "You et al\\.",
      "year" : 2014
    }, {
      "title" : "Aqueous synthesis of PEGylated copper sulfide nanoparticles for photoacoustic imaging of tumors",
      "author" : [ "K. Ding", "J. Zeng", "L. Jing", "R. Qiao", "C. Liu", "M. Jiao", "Z. Li", "M. Gao" ],
      "venue" : "Nanoscale",
      "citeRegEx" : "Ding et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Ding et al\\.",
      "year" : 2015
    }, {
      "title" : "Visualization of protease activity in civo using an activatable photo-acoustic imaging probe based on",
      "author" : [ "K. Yang", "L. Zhu", "L.M. Nie", "X.L. Sun", "L. Cheng", "C.X. Wu", "G. Niu", "X.Y. Chen", "Z. Liu" ],
      "venue" : "CuS nanoparticles. Theranostics",
      "citeRegEx" : "Yang et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Yang et al\\.",
      "year" : 2014
    }, {
      "title" : "A facile synthesis of versatile Cu2-xS nanoprobe for enhanced MRI and infrared thermal/photoacoustic multimodal imaging",
      "author" : [ "J. Mou", "C. Liu", "P. Li", "Y. Chen", "H. Xu", "C. Wei", "L. Song", "J. Shi", "H. Chen" ],
      "venue" : "Biomaterials",
      "citeRegEx" : "Mou et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Mou et al\\.",
      "year" : 2015
    }, {
      "title" : "Compact chelator-free Ni-integrated CuS nanoparticles with tunable near-infrared absorption and enhanced relaxivity for in vivo",
      "author" : [ "D. Gao", "P. Zhang", "C. Liu", "C. Chen", "G. Gao", "Y. Wu", "Z. Sheng", "L. Song", "L. Cai" ],
      "venue" : "dual-modal photoacoustic/MR imaging. Nanoscale,",
      "citeRegEx" : "Gao et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Gao et al\\.",
      "year" : 2015
    }, {
      "title" : "Surface plasmon resonance enhanced light absorption and photothermal therapy in the second near-infrared window",
      "author" : [ "X. Ding", "C.H. Liow", "M. Zhang", "R. Huang", "C. Li", "H. Shen", "M. Liu", "Y. Zou", "N. Gao", "Z Zhang" ],
      "venue" : "J. Am. Chem",
      "citeRegEx" : "Ding et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Ding et al\\.",
      "year" : 2014
    }, {
      "title" : "Copper sulfide self-assembly architectures with improved photothermal",
      "author" : [ "X.Y. Bu", "D. Zhou", "J. Li", "X. Zhang", "K. Zhang", "H. Zhang", "B. Yang" ],
      "venue" : "performance. Langmuir",
      "citeRegEx" : "Bu et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Bu et al\\.",
      "year" : 2014
    }, {
      "title" : "Hydrophilic flower-like CuS superstructures as an efficient 980 nm laser-driven photothermal agent for ablation of cancer cells",
      "author" : [ "Q. Tian", "M. Tang", "Y. Sun", "R. Zou", "Z. Chen", "M. Zhu", "S. Yang", "J. Wang", "J. Hu" ],
      "venue" : "Adv. Mater",
      "citeRegEx" : "Tian et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Tian et al\\.",
      "year" : 2011
    }, {
      "title" : "A novel photothermal nanocrystals",
      "author" : [ "G.S. Song", "L.B. Han", "W.W. Zou", "Z.Y. Xiao", "X.J. Huang", "Z.Y. Qin", "R.J. Zou", "J.Q. Hu" ],
      "venue" : null,
      "citeRegEx" : "Song et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Song et al\\.",
      "year" : 2014
    }, {
      "title" : "Cu7S4 nanosuperlattices with greatly enhanced photothermal efficiency",
      "author" : [ "J. Cui", "R. Jiang", "S. Xu", "G. Hu", "L. Wang" ],
      "venue" : null,
      "citeRegEx" : "Cui et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Cui et al\\.",
      "year" : 2015
    }, {
      "title" : "Facile synthesis of CuS mesostructures with high photothermal conversion efficiency",
      "author" : [ "L. Tan", "Z. Wu", "X. Wang", "J. Sun" ],
      "venue" : "RSC Adv",
      "citeRegEx" : "Tan et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Tan et al\\.",
      "year" : 2015
    }, {
      "title" : "Scalable synthesis of djurleite copper sulphide (Cu1.94S) hexagonal nanoplates from a single precursor copper thiocyanate and their photothermal properties",
      "author" : [ "D. Yoon", "H. Jin", "S. Ryu", "S. Park", "H. Baik", "S.J. Oh", "S. Haam", "C. Joo", "K. Lee" ],
      "venue" : "CrystEngComm",
      "citeRegEx" : "Yoon et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Yoon et al\\.",
      "year" : 2015
    }, {
      "title" : "Synthesis of ultrastable copper sulfide nanoclusters via trapping the reaction intermediate: potential anticancer and antibacterial applications",
      "author" : [ "H.Y. Wang", "X.W. Hua", "F.G. Wu", "B. Li", "P. Liu", "N. Gu", "Z. Wang", "Z. Chen" ],
      "venue" : "ACS Appl. Mater. Interfaces",
      "citeRegEx" : "Wang et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2015
    }, {
      "title" : "Facile synthesis of biocompatible cysteine-coated CuS nanoparticles with high photothermal conversion efficiency for cancer therapy",
      "author" : [ "X.J. Liu", "B. Li", "F.F. Fu", "K.B. Xu", "R.J. Zou", "Q. Wang", "B.J. Zhang", "Z.G. Chen", "J.Q. Hu" ],
      "venue" : "Dalton Trans",
      "citeRegEx" : "Liu et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 2014
    }, {
      "title" : "Copper sulfide nanoparticles with phospholipid-PEG coating for in vivo near-infrared photothermal cancer therapy",
      "author" : [ "Y.Z. Huang", "Y.L. Lai", "S.G. Shi", "S.F. Hao", "J.P. Wei", "X.L. Chen" ],
      "venue" : "Chem. Asian J.10,",
      "citeRegEx" : "Huang et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Huang et al\\.",
      "year" : 2015
    }, {
      "title" : "BSA-directed synthesis of CuS nanoparticles as a biocompatible photothermal agent for tumor ablation in vivo",
      "author" : [ "C. Zhang", "Y.Y. Fu", "X. Zhang", "C. Yu", "Y. Zhao", "S.K. Sun" ],
      "venue" : "Dalton Trans",
      "citeRegEx" : "Zhang et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Zhang et al\\.",
      "year" : 2015
    }, {
      "title" : "Monodisperse copper chalcogenide nanocrystals: controllable synthesis and the pinning of plasmonic resonance absorption",
      "author" : [ "F. Wang", "Q. Li", "L. Lin", "H. Peng", "Z. Liu", "D. Xu" ],
      "venue" : "J. Am. Chem",
      "citeRegEx" : "Wang et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2015
    }, {
      "title" : "Controlling the size, shape, phase, band gap, and localized surface plasmon resonance",
      "author" : [ "X. Wang", "M.T. Swihart" ],
      "venue" : null,
      "citeRegEx" : "Wang and Swihart,? \\Q2015\\E",
      "shortCiteRegEx" : "Wang and Swihart",
      "year" : 2015
    }, {
      "title" : "Theranostic CuS nanoparticles targeting folate receptors for PET image-guided photothermal therapy",
      "author" : [ "M. Zhou", "S. Song", "J. Zhao", "M. Tian", "C. Li" ],
      "venue" : "J. Mater. Chem. B",
      "citeRegEx" : "Zhou et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Zhou et al\\.",
      "year" : 2015
    }, {
      "title" : "Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research",
      "author" : [ "C.J. Anderson", "R. Ferdani" ],
      "venue" : "Cancer Biotherapy Radiopharm",
      "citeRegEx" : "Anderson and Ferdani,? \\Q2009\\E",
      "shortCiteRegEx" : "Anderson and Ferdani",
      "year" : 2009
    }, {
      "title" : "Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy",
      "author" : [ "J. Lewis", "R. Laforest", "T. Buettner", "S. Song", "Y. Fujibayashi", "J. Connett", "M. Welch" ],
      "venue" : "P. Natl. Acad. Sci. USA",
      "citeRegEx" : "Lewis et al\\.,? \\Q2001\\E",
      "shortCiteRegEx" : "Lewis et al\\.",
      "year" : 2001
    }, {
      "title" : "Imaging-guided combined photothermal and radiotherapy to treat subcutaneous and metastatic tumors using iodine-131-doped copper sulfide nanoparticles",
      "author" : [ "Y. Yi", "K. Yang", "C. Liang", "X. Zhong", "P. Ning", "G. Song", "D. Wang", "C. Ge", "C. Chen", "Z Chai" ],
      "venue" : "Adv. Funct. Mater",
      "citeRegEx" : "Yi et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Yi et al\\.",
      "year" : 2015
    }, {
      "title" : "Imaging and photodynamic therapy: mechanisms, monitoring, and optimization",
      "author" : [ "J.P. Celli", "B.Q. Spring", "I. Rizvi", "C.L. Evans", "K.S. Samkoe", "S. Verma", "B.W. Pogue", "T. Hasan" ],
      "venue" : "Chem. Rev",
      "citeRegEx" : "Celli et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Celli et al\\.",
      "year" : 2010
    }, {
      "title" : "Plasmonic copper sulfide nanocrystals exhibiting near-infrared photothermal and photodynamic therapeutic effects",
      "author" : [ "S. Wang", "A. Riedinger", "H. Li", "C. Fu", "H. Liu", "L. Li", "T. Liu", "L. Tan", "M.J. Barthel", "G Pugliese" ],
      "venue" : "ACS Nano",
      "citeRegEx" : "Wang et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2015
    }, {
      "title" : "Hollow copper sulfide nanoparticle-mediated transdermal drug",
      "author" : [ "S. Ramadan", "L.R. Guo", "Y.J. Li", "B.F. Yan", "W. Lu" ],
      "venue" : "delivery. Small",
      "citeRegEx" : "Ramadan et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Ramadan et al\\.",
      "year" : 2012
    }, {
      "title" : "A low-toxic multifunctional nanoplatform based on",
      "author" : [ "G.S. Song", "Q.A. Wang", "Y. Wang", "G. Lv", "C. Li", "R.J. Zou", "Z.G. Chen", "Z.Y. Qin", "K.K. Huo", "Hu", "R. G" ],
      "venue" : null,
      "citeRegEx" : "Song et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Song et al\\.",
      "year" : 2013
    }, {
      "title" : "Combinatorial photothermal and immuno cancer therapy using chitosan-coated hollow copper sulfide nanoparticles",
      "author" : [ "L.R. Guo", "D.D. Yan", "D.F. Yang", "Y.J. Li", "X.D. Wang", "O. Zalewski", "B.F. Yan", "W. Lu" ],
      "venue" : "ACS Nano",
      "citeRegEx" : "Guo et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Guo et al\\.",
      "year" : 2014
    }, {
      "title" : "Hydrophobic anticancer drug delivery by a 980 nm Laser-driven photothermal vehicle for efficient synergistic therapy of cancer cells in vivo",
      "author" : [ "K. Dong", "Z. Liu", "Z.H. Li", "J.S. Ren", "X.G. Qu" ],
      "venue" : "Adv. Mater",
      "citeRegEx" : "Dong et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Dong et al\\.",
      "year" : 2013
    }, {
      "title" : "Ultra-high payload of doxorubicin and pH-responsive drug release in CuS nanocages for a combination of chemotherapy and photothermal therapy",
      "author" : [ "Y. Wang", "Y. Xiao", "H.Y. Zhou", "W. Chen", "R.K. Tang" ],
      "venue" : "RSC Adv",
      "citeRegEx" : "Wang et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2013
    }, {
      "title" : "Folic acid-conjugated hollow mesoporous silica/CuS nanocomposites as a difunctional nanoplatform for targeted chemo-photothermal therapy of cancer cells",
      "author" : [ "X.J. Liu", "F.F. Fu", "K.B. Xu", "R.J. Zou", "J.M. Yang", "Q. Wang", "Q. Liu", "Z.Y. Xiao", "J.Q. Hu" ],
      "venue" : "J. Mater. Chem. B",
      "citeRegEx" : "Liu et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 2014
    }, {
      "title" : "DOX-Cu9S5@mSiO2-PG composite fibers for orthotopic synergistic chemoand photothermal tumor therapy",
      "author" : [ "Y.Y. Chen", "Z.Y. Hou", "B. Liu", "S.S. Huang", "C.X. Li", "J. Lin" ],
      "venue" : "Dalton Trans",
      "citeRegEx" : "Chen et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Chen et al\\.",
      "year" : 2015
    }, {
      "title" : "An NIR-triggered and thermally responsive drug delivery platform through DNA/copper sulfide",
      "author" : [ "L. Zhang", "Y. Li", "Z. Jin", "J.C. Yu", "K.M. Chan" ],
      "venue" : "gates. Nanoscale",
      "citeRegEx" : "Zhang et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Zhang et al\\.",
      "year" : 2015
    }, {
      "title" : "Multifunctional PEG modified DOX loaded mesoporous silica",
      "author" : [ "L. Wu", "M. Wu", "Y. Zeng", "D. Zhang", "A. Zheng", "X. Liu", "J. Liu" ],
      "venue" : null,
      "citeRegEx" : "Wu et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Wu et al\\.",
      "year" : 2015
    }, {
      "title" : "Advances in image-guided radiation therapy",
      "author" : [ "L.A. Dawson", "D.A. Jaffray" ],
      "venue" : "J. Clin. Oncol",
      "citeRegEx" : "Dawson and Jaffray,? \\Q2007\\E",
      "shortCiteRegEx" : "Dawson and Jaffray",
      "year" : 2007
    }, {
      "title" : "Image-guided cancer therapy using PET/CT",
      "author" : [ "J.T. Yap", "J.P. Carney", "N.C. Hall", "D.W. Townsend" ],
      "venue" : "Cancer J",
      "citeRegEx" : "Yap et al\\.,? \\Q2004\\E",
      "shortCiteRegEx" : "Yap et al\\.",
      "year" : 2004
    }, {
      "title" : "Image guided therapy: the advent of theranostic agents",
      "author" : [ "E. Terreno", "F. Uggeri", "S. Aime" ],
      "venue" : "J. Control. Release",
      "citeRegEx" : "Terreno et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Terreno et al\\.",
      "year" : 2012
    }, {
      "title" : "Sub-10 nm",
      "author" : [ "Q.W. Tian", "J.Q. Hu", "Y.H. Zhu", "R.J. Zou", "Z.G. Chen", "S.P. Yang", "R.W. Li", "Q.Q. Su", "Y. Han", "X.G. Liu" ],
      "venue" : null,
      "citeRegEx" : "Tian et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Tian et al\\.",
      "year" : 2013
    }, {
      "title" : "Gadolinium-chelate functionalized copper sulphide as a nanotheranostic agent for MR imaging and photothermal destruction of cancer cells",
      "author" : [ "S.H. Zhang", "Z.B. Zha", "X.L. Yue", "X.L. Liang", "Z.F. Dai" ],
      "venue" : "Chem. Commun",
      "citeRegEx" : "Zhang et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Zhang et al\\.",
      "year" : 2013
    }, {
      "title" : "Enzyme-responsive copper sulphide nanoparticles for combined photoacoustic imaging, tumor-selective chemotherapy and photothermal therapy",
      "author" : [ "Z.B. Zha", "S.H. Zhang", "Z.J. Deng", "Y.Y. Li", "C.H. Li", "Z.F. Dai" ],
      "venue" : "Chem. Commun",
      "citeRegEx" : "Zha et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Zha et al\\.",
      "year" : 2013
    }, {
      "title" : "Activatable hyaluronic acid nanoparticle as a theranostic agent for optical/photoacoustic image-guided photothermal therapy",
      "author" : [ "L.W. Zhang", "S. Gao", "F. Zhang", "K. Yang", "Q.J. Ma", "L. Zhu" ],
      "venue" : "ACS Nano",
      "citeRegEx" : "Zhang et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Zhang et al\\.",
      "year" : 2014
    }, {
      "title" : "Ultrasmall Cu2-xS nanodots for highly efficient photoacoustic imaging-guided photothermal therapy",
      "author" : [ "J. Mou", "P. Li", "C. Liu", "H. Xu", "L. Song", "J. Wang", "K. Zhang", "Y. Chen", "J. Shi", "H. Chen" ],
      "venue" : "Small 11,",
      "citeRegEx" : "Mou et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Mou et al\\.",
      "year" : 2015
    }, {
      "title" : "Photothermal theragnosis",
      "author" : [ "B. Li", "K.C. Ye", "Y.X. Zhang", "J.B. Qin", "R.J. Zou", "K.B. Xu", "X.J. Huang", "Z.Y. Xiao", "W.J. Zhang", "Lu", "X. W" ],
      "venue" : null,
      "citeRegEx" : "Li et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Li et al\\.",
      "year" : 2015
    }, {
      "title" : "In vivo tumor vasculature targeting of CuS@MSN based theranostic nanomedicine",
      "author" : [ "F. Chen", "H. Hong", "S. Goel", "S.A. Graves", "H. Orbay", "E.B. Ehlerding", "S. Shi", "C.P. Theuer", "R.J. Nickles", "W. Cai" ],
      "venue" : "ACS Nano",
      "citeRegEx" : "Chen et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Chen et al\\.",
      "year" : 2015
    }, {
      "title" : "A core/satellite multifunctional nanotheranostic for in vivo imaging and tumor eradication by radiation/photothermal synergistic therapy",
      "author" : [ "Q. Xiao", "X. Zheng", "W. Bu", "W. Ge", "S. Zhang", "F. Chen", "H. Xing", "Q. Ren", "W. Fan", "K Zhao" ],
      "venue" : "J. Am. Chem",
      "citeRegEx" : "Xiao et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Xiao et al\\.",
      "year" : 2013
    }, {
      "title" : "Transferrin-directed preparation of red-emitting copper nanoclusters for targeted imaging of transferrin receptor over-expressed cancer cells",
      "author" : [ "T. Zhao", "He", "X.-W", "Li", "W.-Y", "Zhang", "Y.-K" ],
      "venue" : "J. Mater. Chem. B",
      "citeRegEx" : "Zhao et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Zhao et al\\.",
      "year" : 2015
    }, {
      "title" : "DNA-hosted copper nanoclusters for fluorescent identification of single nucleotide polymorphisms",
      "author" : [ "X. Jia", "J. Li", "L. Han", "J. Ren", "X. Yang", "E. Wang" ],
      "venue" : "ACS Nano",
      "citeRegEx" : "Jia et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Jia et al\\.",
      "year" : 2012
    }, {
      "title" : "Stable Cu nanoclusters: from an aggregation-induced emission mechanism to biosensing and catalytic applications",
      "author" : [ "X. Jia", "X. Yang", "J. Li", "D. Liab", "E. Wang" ],
      "venue" : "Chem. Commun",
      "citeRegEx" : "Jia et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Jia et al\\.",
      "year" : 2014
    }, {
      "title" : "Fluorescent metal nanoclusters: from synthesis to applications",
      "author" : [ "J.J. Li", "J.J. Zhu", "K. Xu" ],
      "venue" : "TrAC-Trends in Anal. Chem",
      "citeRegEx" : "Li et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Li et al\\.",
      "year" : 2014
    }, {
      "title" : "Synthesis of cysteine-functionalized water-soluble luminescent copper nanoclusters and their application to the determination of chromium(VI). Microchim",
      "author" : [ "M.L. Cui", "G. Song", "C. Wang", "Q.J. Song" ],
      "venue" : "Acta 182,",
      "citeRegEx" : "Cui et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Cui et al\\.",
      "year" : 2015
    }, {
      "title" : "Rapid sonochemical synthesis of luminescent and paramagnetic copper nanoclusters for bimodal bioimaging",
      "author" : [ "C. Wang", "H. Cheng", "Y. Sun", "Q. Lin", "C. Zhang" ],
      "venue" : "ChemNanoMat",
      "citeRegEx" : "Wang et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2015
    }, {
      "title" : "Renal clearance and degradation of glutathione-coated copper nanoparticles",
      "author" : [ "S. Yang", "S. Sun", "C. Zhou", "G. Hao", "J. Liu", "S. Ramezani", "M. Yu", "X. Sun", "J. Zheng" ],
      "venue" : "Bioconjugate Chem",
      "citeRegEx" : "Yang et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Yang et al\\.",
      "year" : 2015
    }, {
      "title" : "Singlet oxygen mediated DNA degradation by copper nanoparticles: potential towards cytotoxic effect on cancer cells",
      "author" : [ "G.P. Jose", "S. Santra", "S.K. Mandal", "T.K. Sengupta" ],
      "venue" : "J. Nanobiotech",
      "citeRegEx" : "Jose et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Jose et al\\.",
      "year" : 2011
    }, {
      "title" : "Synergistic anticancer activity of fluorescent copper nanoclusters and cisplatin delivered through a hydrogel nanocarrier",
      "author" : [ "R. Ghosh", "U. Goswami", "S.S. Ghosh", "A. Paul", "A. Chattopadhyay" ],
      "venue" : "ACS Appl. Mater. Interfaces",
      "citeRegEx" : "Ghosh et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Ghosh et al\\.",
      "year" : 2015
    }, {
      "title" : "Safety of nanoparticles in medicine",
      "author" : [ "J. Wolfram", "M. Zhu", "Y. Yang", "J. Shen", "E. Gentile", "D. Paolino", "M. Fresta", "G. Nie", "C. Chen", "H Shen" ],
      "venue" : "Curr. Drug Targets",
      "citeRegEx" : "Wolfram et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Wolfram et al\\.",
      "year" : 2014
    }, {
      "title" : "Nanoparticles for biomedical imaging: fundamentals of clinical translation",
      "author" : [ "H.S. Choi", "J.V. Frangioni" ],
      "venue" : "Mol. Imaging",
      "citeRegEx" : "Choi and Frangioni,? \\Q2010\\E",
      "shortCiteRegEx" : "Choi and Frangioni",
      "year" : 2010
    }, {
      "title" : "Design principles for clinical efficacy of cancer nanomedicine: a look into the basics",
      "author" : [ "S. Sengupta", "A. Kulkarni" ],
      "venue" : "ACS Nano",
      "citeRegEx" : "Sengupta and Kulkarni,? \\Q2013\\E",
      "shortCiteRegEx" : "Sengupta and Kulkarni",
      "year" : 2013
    }, {
      "title" : "Copper biochemistry and molecular biology",
      "author" : [ "M.C. Linder", "M. Hazegh-Azam" ],
      "venue" : "Am. J. Clin. Nutr",
      "citeRegEx" : "Linder and Hazegh.Azam,? \\Q1996\\E",
      "shortCiteRegEx" : "Linder and Hazegh.Azam",
      "year" : 1996
    }, {
      "title" : "Iron and copper metabolism",
      "author" : [ "M. Arredondo", "M.T. Nunez" ],
      "venue" : "Mol. Aspects Med",
      "citeRegEx" : "Arredondo and Nunez,? \\Q2005\\E",
      "shortCiteRegEx" : "Arredondo and Nunez",
      "year" : 2005
    }, {
      "title" : "In vitro and in vivo toxicity studies of copper sulfide nanoplates for potential photothermal applications",
      "author" : [ "W. Feng", "W. Nie", "Y. Cheng", "X. Zhou", "L. Chen", "K. Qiu", "Z. Chen", "M. Zhu", "C. He" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "Feng et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Feng et al\\.",
      "year" : 2015
    }, {
      "title" : "A comparative study of hollow copper sulfide nanoparticles and hollow gold nanospheres on degradability and toxicity",
      "author" : [ "D.B. Niesen", "N. Seeram", "Ahmed" ],
      "venue" : "ACS Nano",
      "citeRegEx" : "Niesen et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Niesen et al\\.",
      "year" : 2013
    }, {
      "title" : "Clearance pathways and tumor targeting of imaging nanoparticles",
      "author" : [ "M. Yu", "J. Zheng" ],
      "venue" : "ACS Nano",
      "citeRegEx" : "Yu and Zheng,? \\Q2015\\E",
      "shortCiteRegEx" : "Yu and Zheng",
      "year" : 2015
    } ],
    "referenceMentions" : [ ],
    "year" : 2016,
    "abstractText" : null,
    "creator" : null
  }
}